[Continuous subcutaneous infusion pump for diabetic patients]

Alfie V, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A
Record ID 32018001481
Spanish
Original Title: Sistemas de infusión continua subcutánea de insulina en pacientes diabéticos
Authors' recomendations: CONCLUSIONS No evidence was found on the long-term benefits among type 2 diabetic patients who use the continuous subcutaneous infusion pump when compared with conventional treatment with administration of several daily insulin doses. Moderate-quality evidence suggests that patients with type 1 diabetes mellitus, who did not achieve adequate disease control with conventional treatment, achieve control with subcutaneous system treatments. Very low quality evidence on the use of this technology do not allow drawing conclusions about its efficacy in avoiding long-term complications in adolescents with type 1 diabetes mellitus. Moderate-quality evidence suggests that in patients with type 1 diabetes mellitus, the continuous subcutaneous infusion pump system reduces glycosylated hemoglobin levels, thus achieving slightly better values when compared with several daily insulin injections, and it is associated with fewer episodes of night hypoglycemia. Patient quality of life and satisfaction would be better among those using the continuous subcutaneous infusion pump system than with several daily injections for the treatment of type 1 diabetes. Moderate-quality evidence suggests that in patients with type 2 diabetes mellitus, the continuous subcutaneous infusion pump system when compared with several daily insulin injections does not present differences in the decrease of glycosylated hemoglobin levels or severe hypoglycemia episodes. Most clinical practice guidelines reviewed recommend the insulin infusion pump use for patients with type 1 diabetes mellitus with difficult glucose level control. The public and private health sponsors reviewed from high-income countries as well as the Argentine reimbursement system cover this technology for patients with type 1 diabetes mellitus with poor diseases control. There are no cost-effectiveness studies for this technology in Argentina.
Details
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Diabetes Mellitus, Type 1
  • Insulin Infusion Systems
  • Hypoglycemic Agents
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.